Handelsavisen
prelaunch
Companies Healthcare SHAY.NS
SH
SHAY.NS NSE (India) Healthcare Facilities & Services

Shalby Ltd

$158,12
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
6,4 %
ROE
0,6 %
Net margin
0,6 %
Debt / equity
0,48
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Shalby Ltd operates in the healthcare sector, providing healthcare services and equipment, with a primary focus on pharmaceuticals.

Business. Shalby Ltd (SHAY.NS) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare sector. Shalby Ltd is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target192,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
192,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
0,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SHAY.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SHAY.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Shalby Ltd (SHAY.NS) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare sector. Shalby Ltd is headquartered in India and is listed on the National Stock Exchange of India. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Shalby Ltd's capital structure is characterized by a debt-to-equity ratio of 0.48, indicating a relatively conservative leverage position compared to the industry median. The company's liquidity is assessed as medium, with a current ratio of 1.45, suggesting it can cover its short-term obligations but with limited buffer. However, the company's operating cash flow is negative at -43.42 million INR, and free cash flow is also negative at -16.73 million INR, signaling potential liquidity constraints in the near term.

    Profitability metrics for Shalby Ltd show a return on equity (ROE) of 0.63% and a return on assets (ROA) of 0.37%, both of which are below the industry median for healthcare providers. The company's net income of 62.23 million INR is modest relative to its revenue of 10.87 billion INR, indicating low profitability. Gross profit of 4.52 billion INR represents 41.7% of revenue, which is in line with the industry average, but the operating margin of 6.4% is below the median for the sector.

    Geographically, Shalby Ltd's revenue is concentrated in India, with no disclosed international operations. The company's business is primarily driven by its domestic healthcare services and pharmaceuticals segments. There is no detailed breakdown of revenue by business segment in the latest financial data, but the company's primary activity is in pharmaceuticals.

    The company's growth trajectory is mixed. Revenue for the latest period is reported at 10.87 billion INR, but there is no year-over-year growth data provided. Analysts have assigned a mean price target of 192.00 INR, with a single "buy" recommendation and no "strong buy" or "hold" ratings. This suggests limited optimism about the company's near-term growth potential. The company's capital expenditure of -714.46 million INR indicates a significant investment in infrastructure or expansion, which could support future growth if it translates into higher revenue and profitability.

    Risk factors for Shalby Ltd include medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's debt load is manageable, with long-term debt of 4.76 billion INR, but the negative operating and free cash flows could pose challenges in maintaining debt serviceability. The risk assessment also highlights the need for improved cash flow generation to support ongoing operations and reduce reliance on external financing.

    Recent events and disclosures for Shalby Ltd include the latest financial results, which show a decline in operating and free cash flows. There are no recent filings or transcripts indicating major strategic shifts or regulatory changes. The company's financial performance and capital structure suggest a need for operational improvements to enhance profitability and cash flow generation.

    Key takeaways
    • Shalby Ltd has a conservative debt-to-equity ratio of 0.48, but its liquidity is assessed as medium due to negative operating and free cash flows.
    • The company's profitability is weak, with ROE and ROA below the industry median, and a low operating margin of 6.4%.
    • Revenue is concentrated in India, with no disclosed international operations, and the company's primary activity is in pharmaceuticals.
    • Analysts have assigned a mean price target of 192.00 INR, with only one "buy" recommendation, indicating limited near-term growth expectations.
    • The company's capital expenditure of -714.46 million INR suggests ongoing investment in infrastructure or expansion, which could support future growth if it translates into higher revenue and profitability.
    • Risk factors include medium liquidity risk and the need for improved cash flow generation to support ongoing operations and reduce reliance on external financing.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $158,12
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $9.92B
    Net cash
    -$4.76B
    Current ratio
    1.4
    Debt / equity
    0.5
    ROA
    0.4%
    ROE
    0.6%
    Cash conversion
    -70.0%
    CapEx / revenue
    -6.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,80
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-15 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,80
    Revenueno estimateno estimate11,3B INR
    Operating incomeno estimateno estimate738,0M INR
    Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$192,00 · Median $192,00
    Low $192,00High $192,00
    Operating income · consensus738,0M INR
    EPS surprise
    −90,0 %
    reported vs consensus · miss
    Revenue surprise
    −3,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$192,00
    Mean$192,00
    Median$192,00
    High$192,00
    Spot$158,12
    +21.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,4 %Below median
    Net Margin0,6 %Below median
    ROE0,6 %Below median
    Capex / Rev-6,6 %Above median
    D/E0,48Below median
    Cash Conv-0,70Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Shalby Ltd Market data — financials · 2026-05-29
    • Shalby Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SHAY.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage